Close Menu

NEW YORK (GenomeWeb) – Biocartis is expanding into the oncology space with a planned series of immunotherapy and liquid biopsy assays on its flagship Idylla molecular testing platform.

The Belgian firm last week laid out plans for liquid biopsy panels for guiding therapy selection for cancer patients and monitoring therapy response, post-therapy minimal residual disease (MRD), and recurrence.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.